The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to suppress T-cell activity and evade anti-tumor immunity.
• PD-L1 interacts with Programmed death receptor 1 (PD-1) on lymphocytes, acting as a crucial immune checkpoint.
• Chemotherapy has been observed to enhance PD-L1 expression via various proliferation pathways.

Purpose of the Study:

• To review the impact of chemotherapy on PD-L1 expression.
• To evaluate PD-L1's role as a prognostic and predictive marker in patients undergoing neoadjuvant chemotherapy (NAC).
• To discuss the clinical utility of PD-L1 as a biomarker in NAC.

Main Methods:

• Literature review focusing on studies investigating PD-L1 expression in cancer.
• Analysis of research on chemotherapy's effect on PD-L1 levels.
• Synthesis of data regarding PD-L1's predictive and prognostic value in NAC settings.

Main Results:

• Chemotherapy can enhance PD-L1 expression in cancer cells.
• The predictive and prognostic significance of PD-L1 in NAC-treated patients requires further establishment.
• PD-L1's role as a biomarker in NAC is under investigation.

Conclusions:

• Chemotherapy influences PD-L1 expression, a key molecule in immune evasion.
• Further research is needed to validate PD-L1 as a reliable prognostic and predictive marker for NAC.
• Understanding PD-L1's modulation by chemotherapy may inform clinical practice and treatment strategies.